A5051423361- Neuropeptides and Animal Physiology
- Helicobacter pylori-related gastroenterology studies
- Gastroesophageal reflux and treatments
- Liver Disease and Transplantation
- Diabetes Treatment and Management
- Drug Transport and Resistance Mechanisms
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Clinical Nutrition and Gastroenterology
- Esophageal and GI Pathology
- Biliary and Gastrointestinal Fistulas
- Biochemical Analysis and Sensing Techniques
- Abdominal Surgery and Complications
- Hormonal Regulation and Hypertension
- Nitric Oxide and Endothelin Effects
- Organ Transplantation Techniques and Outcomes
- Diet and metabolism studies
- Intestinal and Peritoneal Adhesions
- Receptor Mechanisms and Signaling
- Diverticular Disease and Complications
- Infant Nutrition and Health
- Amoebic Infections and Treatments
- Drug-Induced Hepatotoxicity and Protection
- Enhanced Recovery After Surgery
- Protein Hydrolysis and Bioactive Peptides
University of Zagreb
2014-2025
Abstract Background and purpose We focused on the, yet undescribed, therapy effect of the stable gastric pentadecapeptide BPC 157 in hippocampal ischemia/reperfusion injuries, after bilateral clamping common carotid arteries rats. The background is proven injuries different tissues. Furthermore, there subsequent oxidative stress counteraction, particularly when given during reperfusion. recovering it has occluded vessels, results with activation alternative pathways, bypassing occlusion deep...
The Pringle maneuver [portal triad obstruction(PTO)] provides huge disturbances during ischemia and even more thereafter in reperfusion. Contrarily, a possible solution may be stable gastric pentadecapeptide BPC 157, with already documented beneficial effects ischemia/reperfusion conditions. Recently, as cytoprotective agent, successfully resolved vessel occlusions rats (ischemic colitis; deep vein thrombosis, superior anterior pancreaticoduodenal vein; bile duct cirrhosis) through rapid...
Recently, as a possible therapy resolving solution, pentadecapeptide BPC 157 therapy, has been used in alleviating various vascular occlusion disturbances. was previously reviewed novel mediator of Robert cytoprotection and endothelium protection the stomach, gut-brain axis, beneficial gastrointestinal tract, with particular reference to recruitment, ulcerative colitis tumor cachexia, other tissues healing. Here we raised new hypothesis about Budd-Chiari syndrome rats, rapid bypassing...
We highlight the particular aspects of stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity (not destroyed in human juice, native and as a cytoprotection mediator holds response specifically related to preventing or recovering damage such) its possible relations with neurotransmitter activity. attempt resolve shortage effects 157, given general standard criteria, classic terms. substitute lack direct conclusive evidence (i.e., production within neuron present it precursor...
AIMTo investigate whether duodenal lesions induced by major venous occlusions can be attenuated BPC 157 regardless nitric oxide (NO) system involvement. METHODSMale Wistar rats underwent superior anterior pancreaticoduodenal vein (SAPDV)-ligation and were treated with a bath at the ligated SAPDV site (BPC 10 μg, ng/kg per 1 mL bath/rat; L-NAME 5 mg/kg L-arginine 100 bath/rat, alone and/or together; or μg/kg instilled into rat stomach, min ligation-time).We recorded vessel presentation...
Background. We investigated the occluded essential vessel tributaries, both arterial and venous, superior mesenteric vein artery in rats, consequent noxious syndrome, peripherally centrally. As therapy, we hypothesized rapidly activated alternative bypassing pathways, stable gastric pentadecapeptide BPC 157 since it alleviated venous occlusion syndromes. Methods. Assessments were performed for 30 min (gross recording, venography, ECG, pressure, microscopy, biochemistry, oxidative stress),...
Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to abdominal aorta. Previously, when confronted with major vessel occlusion, its effect would rapidly activate collateral pathways and resolve venous syndromes (Pringle maneuver ischemia, reperfusion, Budd–Chiari syndrome) rats. This overwhelm result local, peripheral, central disturbances. Methods: Assessments, for 30 min...
Background. Gastric pentadecapeptide BPC 157 therapy in rats compensated irremovable occlusion of various vessels and counteracted the consequent multiorgan dysfunction syndromes by activation corresponding collateral bypassing loops. Thus, we used against end superior mesenteric vein. Methods. Assessments, for 30 min (gross recording, venography, ECG, pressure, microscopy, biochemistry, oxidative stress) include portal caval hypertension, aortal hypotension, centrally, sagittal sinus...
We revealed that the stable gastric pentadecapeptide BPC 157, a useful peptide therapy against isoprenaline myocardial infarction, as well reinfarction, may follow counteraction of recently described occlusion-like syndrome, induced peripherally and centrally, which was for first time in isoprenaline-treated rats. 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg L-arginine (200 i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) 5 after (75 150 s.c.). At 75 s.c., we...
Abstract: This review explores the therapeutic potential of stable gastric pentadecapeptide BPC 157 in addressing electrolyte imbalances, specifically hyperkalemia, hypokalemia, hypermagnesemia, and hyperlithemia. In demonstrated a comprehensive counteractive effect against KCl overdose (intraperitoneally, intragastrically, vitro), effectively mitigating symptoms such as muscular weakness, hypertension, sphincter dysfunction, arrhythmias, lethality. It also counteracted adverse effects...
We redefined Robert's prototypical cytoprotection model, namely the intragastric administration of 96% alcohol in order to generate a general peripheral and central syndrome similar that which occurs when major or veins are occluded animal models. With this redefinition, we used model examine cytoprotective effects stable gastric pentadecapeptide BPC 157. The induced lesions, intracranial (superior sagittal sinus) hypertension, severe brain swelling portal vena caval aortal hypotension,...
Due to endothelial impairment, high-dose lithium may produce an occlusive-like syndrome, comparable permanent occlusion of major vessel-induced syndromes in rats; intracranial, portal, and caval hypertension, aortal hypotension; multi-organ dysfunction syndrome; brain, heart, lung, liver, kidney, gastrointestinal lesions; arterial venous thrombosis; tissue oxidative stress. Stable gastric pentadecapeptide BPC 157 be a means therapy via activating loops (bypassing vessel occlusion)...
We revealed the therapy effect of stable gastric pentadecapeptide BPC 157 (10 μg/kg, 10 ng/kg ig or po) with specific activation collateral rescuing pathways, azygos vein, on bile duct ligation in particular, and acute pancreatitis as local disturbances (i.e., improved gross microscopy presentation, decreased amylase level). Additionally, we therapy's vascular failure multiorgan failure, both peripherally centrally following "occlusion-like" syndrome, major intoxication (alcohol, lithium),...